Research Article

Long-term incidence of colorectal cancer after bariatric surgery or usual care in the Swedish Obese Subjects study

Magdalena Taube1*, Markku Peltonen2,3, Kajsa Sjöholm1, Richard Palmqvist4, Johanna C. Andersson-Assarsson1, Peter Jacobson1, Per-Arne Svensson1,5, Lena M. S. Carlsson1

1 Department of Molecular and Clinical medicine, Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, 2 Public Health Promotion Unit, National Institute for Health and Welfare, Helsinki, Finland, 3 Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden, 4 Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden, 5 Institute of Health and Care Sciences, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

* Magdalena.Taube@gu.se

Abstract

Bariatric surgery in patients with obesity is generally considered to reduce cancer risk in patients with obesity. However, for colorectal cancer some studies report an increased risk with bariatric surgery, whereas others report a decreased risk. These conflicting results demonstrate the need of more long-term studies analyzing the effect of bariatric surgery on colorectal cancer risk. Therefore, data from the Swedish Obese Subjects (SOS) study, ClinicalTrials.gov identifier: NCT01479452, was used to examine the impact of bariatric surgery on long-term incidence of colorectal cancer. The SOS study includes 2007 patients who underwent bariatric surgery and 2040 contemporaneously matched controls who received conventional obesity treatment. Patients in the surgery group underwent gastric bypass (n = 266), banding (n = 376) or vertical banded gastroplasty (n = 1365). Information on colorectal cancer events was obtained from the Swedish National Cancer Registry. Median follow-up was 22.2 years (inter-quartile range 18.3–25.2). During follow up there were 58 colorectal cancer events in the surgery group and 67 colorectal cancer events in the matched control group with a hazard ratio (HR) of 0.79 (95% CI:0.55–1.12; p = 0.183). After adjusting for age, body mass index, alcohol intake, smoking status, and diabetes, the adjusted HR was 0.89 (95% CI:0.62–1.29; p = 0.551). When analyzing rectal cancer events separately- 19 events in the surgery group and 31 events in the control group-a decreased risk of rectal cancer with surgery was observed (HR = 0.56; 95% CI:0.32–0.99; p = 0.045, adjusted HR = 0.61 (95% CI:0.34–1.10; p = 0.099), while the risk of colon cancer was unchanged. To conclude- in this long-term, prospective study, bariatric surgery was not associated with altered colorectal cancer risk.

PLOS ONE | https://doi.org/10.1371/journal.pone.0248550 March 25, 2021 1 / 7
Introduction

It is well established that the risk of several cancers, including colorectal cancer (CRC), is increased in patients with obesity [1–3]. Bariatric surgery leads to sustained weight-loss, and is associated with reduced overall cancer risk, especially in women [4–6]. Although bariatric surgery has been shown to reduce the risk of obesity-related cancer in general [7], whether the incidence of CRC increases or decreases after this treatment is debated [8].

Retrospective studies in multi-country cohorts have reported an increased risk of CRC with bariatric surgery [9,10]. In contrast, other studies including a meta-analysis of registry-based, retrospective studies have found that bariatric surgery is associated with a decreased risk of CRC [7,11,12]. Factors that may explain these conflicting results include differences in age of patients at inclusion, that various bariatric surgery techniques are used, and choice of statistical method. Given the latency period in colorectal carcinogenesis, the effects of bariatric surgery on subsequent risk of CRC may take decades to become evident and sufficient follow-up periods are therefore also important.

To better understand the effect of bariatric surgery on CRC and other obesity-related types of cancer it is therefore important to use different study populations undergoing various bariatric surgery techniques with long follow-up. To this end, we have examined the long-term incidence of CRC after bariatric surgery and usual care in the Swedish Obese Subjects (SOS) study, an ongoing, matched, prospective, controlled intervention study investigating effects of bariatric surgery.

Materials and methods

The SOS study protocol, clinical identifier NCT01479452, was approved by seven regional ethics committees in Sweden: Umeå universitet, Medicinska fakulteten, Forskningssetiska kommittén, Karolinska Institutets regionala forskningsetiska kommitté, Lunds Universitet, Medicinska fakultetens forskningssetiska kommitté, Hälsouniversitetet Linköping, Forskningsetiska kommittén, Forskningsetiska kommittén vid Uppsala universitet, Örebro Forskningsetiska kommittén i Örebro, Göteborg Medicinska fakultetens Forskningsetiska kommitté, and written or oral informed consent was obtained from all participants. The ongoing, prospective matched SOS study compares bariatric surgery with conventional obesity treatment [13–16]. In brief, the study enrolled 4047 patients with obesity recruited through campaigns in mass media and at surgical departments and primary health care centres in Sweden between September 1, 1987 and January 31, 2001. Inclusion criteria were age between 37 and 60 years and body-mass index (BMI) (weight in kilograms divided by square of height in meters) of ≥34 for men and ≥38 for women. The exclusion criteria were identical in the treatment groups and aimed to obtain an operable surgical group. The surgery group included 2007 patients of which 376 underwent gastric banding, 1365 vertical banded gastroplasty, and 266 gastric bypass surgery. The control group (n = 2040), received usual obesity treatment and was matched to the surgery group using 18 variables [17]. The intervention study began on the day of surgery for both the surgically treated patient and the matched control patient. Surgery and control patients underwent a baseline examination approximately four weeks before the start of intervention. Clinical examinations were carried out after 0.5, 1, 2, 3, 4, 6, 8, 10, 15 and 20 years. Centralized biochemical examinations were carried out at matching and baseline examinations, and after 2, 10, 15 and 20 years. In addition, questionnaires were filled out at every clinical examination. Colon and rectal cancer events were identified in the Swedish National Cancer Registry using ICD7 codes 153 and 154. The Swedish National Cancer Registry has over 95% coverage for all malignant tumours of which 99% are morphologically verified [18]. In addition, data on death and emigration were obtained by crosschecking social security
numbers from the SOS database with the Cause of Death Registry and the Registry of the Total Population. Patients with pre-operative CRC, two controls and one surgery patient, were excluded from the analyses. Kaplan-Meier estimates of cumulative incidence rates were performed to compare time to first cancer diagnosis between the treatment groups. The analyses were performed per-protocol, thus, all participants were included in their original study group until any bariatric surgery was performed in the control group or there was a change in, or removal of, the bariatric surgical procedure in the surgery group, after which they were censored from the analysis. Multivariable Cox proportional hazard models were performed to analyze the impact of potential baseline confounders; age, BMI, alcohol intake, smoking status, and diabetes. The cut-off date for the analysis was December 31, 2018. Median follow-up was 22.2 years (inter-quartile range 18.3–25.2) and follow-up rate was 99.9%.

Results

At baseline, patients in the surgery group were on average one year younger, but most metabolic risk factors were worse compared to the control group (Table 1).

After bariatric surgery, mean weight losses (SD) were 28.7 (14.3) kg, 21.1 (15.1) kg, 21.6 (16.6) kg and 22.1 (16.5) kg at the 2-, 10-, 15 and 20-year follow-up visits, respectively (Fig 1). The mean weight changes in the control group were small, and never exceeded 3 kg in gain or loss. No differences in incidences of CRC, HR = 0.79 (95% CI:0.55–1.12; p = 0.183), adjHR = 0.89 (95% CI:0.62–1.29; p = 0.551), or colon cancer, HR = 0.98 (95% CI: 0.64–1.50; p = 0.923), adjHR = 1.14 (95% CI:0.72–1.80; p = 0.572) were observed between treatment groups (Fig 2).

Table 1. Baseline characteristics of the Swedish Obese Subjects study participants.

| Characteristic                  | Control Group (n = 2038) | Surgery Group(n = 2006) | p-value |
|--------------------------------|--------------------------|-------------------------|---------|
| Female No (%)                  | 1445 (70.9)              | 1419 (70.7)             | 0.908   |
| Age (yr)                       | 48.7±6.3                 | 47.2±5.9                | <0.001  |
| Weight (kg)                    | 114.7±16.5               | 120.9±16.6              | <0.001  |
| Height (cm)                    | 169.0±9.2                | 168.9±9.1               | 0.587   |
| Body-mass index (kg/m2)        | 40.1±4.7                 | 42.4±4.5                | <0.001  |
| Sagittal diameter (cm)         | 27.4±3.7                 | 28.9±3.7                | <0.001  |
| Blood glucose (mg/dL)          | 88±32                    | 94±36                   | <0.001  |
| Serum insulin (mU/l)           | 18.0±11.4                | 21.5±13.7               | <0.001  |
| Blood pressure (mm Hg)         |                          |                         |         |
| Systolic                       | 137.9±18.0               | 145.0±18.8              | <0.001  |
| Diastolic                      | 85.2±10.7                | 89.9±11.1               | <0.001  |
| Lipid levels (mg/dL)           |                          |                         |         |
| Total cholesterol              | 216±42                   | 228±42                  | <0.001  |
| HDL cholesterol                | 50±12                    | 54±12                   | 0.845   |
| Triglycerides                  | 177±124                  | 195±133                 | <0.001  |
| Alcohol consumption (g/day)    | 5.3±8.1                  | 5.2±7.2                 | 0.632   |
| Daily smoking No (%)           | 421 (20.8)               | 518 (25.8)              | <0.001  |
| Diabetes at baseline No (%)    | 262 (12.9)               | 344 (17.2)              | <0.001  |

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); HDL-C, high-density lipoprotein cholesterol. SI conversion factors: To convert glucose to millimoles per liter, multiply by 0.0555; to convert insulin to picomoles per liter, multiply by 6.945; to convert total cholesterol and HDL-C to millimoles per liter, multiply by 0.0259; and to convert triglycerides to millimoles per liter, multiply by 0.0113.

*Data are presented as mean (SD) unless otherwise indicated.

https://doi.org/10.1371/journal.pone.0248550.t001
However, a decreased risk of rectal cancer in the surgical group was observed, HR = 0.56 (95% CI 0.32–0.99; p = 0.045), but when adjusted for age, BMI, alcohol intake, smoking status and diabetes the statistical significance was lost adjHR = 0.61 (95% CI 0.34–1.10; p = 0.099). In the surgery and control groups, respectively, there were 40 and 45 CRC events in women (adjHR = 0.89, 95% CI 0.57–1.40; p = 0.615) and 18 and 22 CRC events in men (adjHR = 0.90, 95% CI 0.48–1.69; p = 0.747).

**Discussion**

Data from the prospective SOS-study, which compares a bariatric surgery group with a matched control group, could not confirm that bariatric surgery is associated with an altered...
risk of CRC. However, in an unadjusted analysis, we observed a decreased risk of rectal cancer with surgery. This is in line with Christou et al, reporting a clinically important, relative risk of CRC with surgery of 0.32 (95% CI 0.076–1.313; p = 0.063) [19]. Future studies with larger cohorts and a greater number of rectal cancer events may strengthen this finding.

We can only speculate about the differences between the SOS study and recent retrospective studies reporting either increased or decreased risk of CRC following bariatric surgery [8]. New surgery techniques have been developed during the long follow up period. It is possible that various bariatric surgery techniques may affect the colonic epithelium, and thereby the expression of mucosal CRC biomarkers, in different ways. It has been reported that pro-inflammatory and tumorigenic COX-1 levels increase 6 months after Roux-en-Y gastric bypass (RYGB) surgery with a biliopancreatic limb of 150 cm [20], but decreases after RYGB with a shorter biliopancreatic limb [21]. In addition, COX-1 levels are unchanged after sleeve gastrectomy [22]. However, as many environmental and lifestyle factors influence the CRC risk, a controlled study design is probably of utmost importance. In the studies reporting an increased risk of CRC with bariatric surgery, known confounders such as smoking or BMI were unknown in the control groups. This may be problematic, not only as BMI is a significant variable that may affect the assessment of surgery outcomes, but also because of the known association between BMI and colon cancer [3]. Future studies exploring altered CRC risk with bariatric surgery should ensure adequate statistical power, either with larger study sizes or higher incidence rates, and diverse bariatric surgery techniques. Nonetheless, it should be noted that in general, bariatric surgery appears to reduce cancer risk and increase longevity [4,5,23].

The SOS study has some limitations. A majority of the patients in the surgery group underwent vertical banded gastroplasty or banding, methods rarely used today. In addition, cancer incidence was not a predefined endpoint, and the study was therefore not designed to address the current research question. Hence, despite a large number of patients and very long follow-up, the number of CRC events was limited. Strengths include the prospective design, the well-characterized matched control group, and the possibility to crosscheck social security numbers of participants with almost 100% complete national registers.

In conclusion, in this prospective controlled study, we could not verify that bariatric surgery is associated with changes in risk of CRC in patients with obesity.

Acknowledgments

We thank the SOS patients and staff members at 480 primary health-care centers and 25 surgical departments in Sweden in which the SOS study was conducted. We acknowledge Christina Torefalk and Björn Henning for invaluable administrative support.

Author Contributions

Conceptualization: Magdalena Taube, Kajsa Sjöholm.

Data curation: Markku Peltonen, Peter Jacobson.

Formal analysis: Markku Peltonen.

Funding acquisition: Lena M. S. Carlsson.

Investigation: Magdalena Taube, Markku Peltonen, Kajsa Sjöholm, Peter Jacobson, Lena M. S. Carlsson.

Methodology: Magdalena Taube, Markku Peltonen, Kajsa Sjöholm.

Project administration: Magdalena Taube.
Resources: Kajsa Sjöholm, Richard Palmqvist, Johanna C. Andersson-Assarsson, Per-Arne Svensson, Lena M. S. Carlsson.

Software: Markku Peltonen, Peter Jacobson.

Supervision: Magdalena Taube, Markku Peltonen, Richard Palmqvist, Lena M. S. Carlsson.

Validation: Magdalena Taube, Richard Palmqvist, Johanna C. Andersson-Assarsson, Per-Arne Svensson.

Visualization: Markku Peltonen.

Writing – original draft: Magdalena Taube.

Writing – review & editing: Markku Peltonen, Kajsa Sjöholm, Richard Palmqvist, Johanna C. Andersson-Assarsson, Peter Jacobson, Per-Arne Svensson, Lena M. S. Carlsson.

References

1. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology. 2007; 132(6):2208–25. https://doi.org/10.1053/j.gastro.2007.03.058 PMID: 17498513

2. Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y, et al. Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLOS One. 2013; 8(1):e53916. https://doi.org/10.1371/journal.pone.0053916 PMID: 23348764

3. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. The Lancet. 2008; 371(9612):569–78. https://doi.org/10.1016/S0140-6736(08)60269-X PMID: 18280327

4. Tee MC, Cao Y, Warnock GL, Hu FB, Chavarro JE. Effect of bariatric surgery on oncologic outcomes: a systematic review and meta-analysis. Surgical endoscopy. 2013; 27(12):4449–56. https://doi.org/10.1007/s00464-013-3127-9 PMID: 23949484

5. Sjöström L, Gummesson A, Sjöström CD, Narbro K, Peltonen M, Wedel H, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. The Lancet Oncology. 2009; 10(7):693–62. https://doi.org/10.1016/S1470-2045(09)70159-7 PMID: 19565163

6. Anveden A, Taube M, Peltonen M, Jacobson P, Andersson-Assarsson JC, Sjöholm K, et al. Long-term incidence of female-specific cancer after bariatric surgery or usual care in the Swedish Obese Subjects Study. Gynecol Oncol. 2017; 145(2):224–9. https://doi.org/10.1016/j.ygyno.2017.02.036 PMID: 28259424

7. Schauer DP, Feigelson HS, Koebnick C, Caan B, Weinmann S, Leonard AC, et al. Bariatric Surgery and the Risk of Cancer in a Large Multisite Cohort. Ann Surg. 2019; 269(1):95–101. https://doi.org/10.1097/SLA.0000000000002525 PMID: 28938270

8. Davidson LE, Adams TD. Does Bariatric Surgery Increase or Reduce Colorectal Cancer Risk-Is the Jury Still Out? JAMA Surg. 2020.

9. Tao W, Artama M, von Euler-Chelpin M, Hull M, Ljung R, Lynge E, et al. Colon and rectal cancer risk after bariatric surgery in a multicountry Nordic cohort study. Int J Cancer. 2019.

10. Mackenzie H, Markar SR, Askari A, Faiz O, Hull M, Purkayastha S, et al. Obesity surgery and risk of cancer. Br J Surg. 2018; 105(12):1650–7. https://doi.org/10.1002/bjs.10914 PMID: 30003539

11. Afshar S, Kelly SB, Seymour K, Lara J, Woodcock S, Mathers JC. The effects of bariatric surgery on colorectal cancer risk: systematic review and meta-analysis. Obes Surg. 2014; 24(10):1793–9. https://doi.org/10.1007/s11695-014-1359-y PMID: 25015708

12. Bailly L, Fabre R, Pradier C, Iannelli A. Colorectal Cancer Risk Following Bariatric Surgery in a Nationwide Study of French Individuals With Obesity. JAMA Surg. 2020.

13. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004; 351(26):2683–93. https://doi.org/10.1056/NEJMoa035622 PMID: 15616203

14. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007; 357(8):741–52. https://doi.org/10.1056/NEJMo066254 PMID: 17715408
15. Sjostrom L, Peltonen M, Jacobson P, Sjostrom CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012; 307(1):56–65. https://doi.org/10.1001/jama.2011.1914 PMID: 22215166

16. Torgerson JS, Lindroos AK, Naslund I, Peltonen M. Gallstones, gallbladder disease, and pancreatitis: cross-sectional and 2-year data from the Swedish Obese Subjects (SOS) and SOS reference studies. Am J Gastroenterol. 2003; 98(5):1032–41. https://doi.org/10.1111/j.1572-0241.2003.07429.x PMID: 12809625

17. Sjostrom L, Larsson B, Backman L, Bengtsson C, Bouchard C, Dahlgren S, et al. Swedish obese subjects (SOS). Recruitment for an intervention study and a selected description of the obese state. Int J Obes Relat Metab Disord. 1992; 16(6):465–79. PMID: 1322873

18. Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009; 48(1):27–33. https://doi.org/10.1080/02841860802247664 PMID: 18767000

19. Christou NV, Lieberman M, Sampalis F, Sampalis JS. Bariatric surgery reduces cancer risk in morbidly obese patients. Surg Obes Relat Dis. 2008; 4(6):691–5. https://doi.org/10.1016/j.soard.2008.08.025 PMID: 19026373

20. Sainsbury A, Goodlad RA, Perry SL, Pollard SG, Robins GG, Hull MA. Increased colorectal epithelial cell proliferation and crypt fission associated with obesity and roux-en-Y gastric bypass. Cancer Epidemiol Biomarkers Prev. 2008; 17(6):1401–10. https://doi.org/10.1158/1055-9965.EPI-07-2874 PMID: 18559555

21. Afshar S, Malcomson F, Kelly SB, Seymour K, Woodcock S, Mathers JC. Biomarkers of Colorectal Cancer Risk Decrease 6 months After Roux-en-Y Gastric Bypass Surgery. Obes Surg. 2018; 28(4):945–54. https://doi.org/10.1007/s11695-017-2953-6 PMID: 28990150

22. Kant P, Perry SL, Dexter SP, Race AD, Loadman PM, Hull MA. Mucosal biomarkers of colorectal cancer risk do not increase at 6 months following sleeve gastrectomy, unlike gastric bypass. Obesity (Silver Spring). 2014; 22(1):202–10.

23. Adams TD, Stroup AM, Gress RE, Adams KF, Calle EE, Smith SC, et al. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring). 2009; 17(4):796–802. https://doi.org/10.1038/oby.2008.616 PMID: 19148123